



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/714,719	11/17/2003	Janel E. Young	ETH5095	2358
27777	7590	06/29/2007		
PHILIP S. JOHNSON JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933-7003			EXAMINER FUBARA, BLESSING M	
			ART UNIT 1618	PAPER NUMBER
			MAIL DATE 06/29/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/714,719	YOUNG ET AL.	
	Examiner	Art Unit	
	Blessing M. Fubara	1618	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 09 April 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-41 is/are pending in the application.
- 4a) Of the above claim(s) 14-41 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-13 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Examiner acknowledges receipt of request for extension of time, response to election/restriction requirement and remarks, all filed 04/09/07. Claims 1-41 are pending.

Election/Restrictions

1. Applicant's election with traverse of Group 1, claims 1-13 in the reply filed on 04/09/07 is acknowledged. The traversal is on the ground(s) that the examiner has not shown that search and examination of the entire application would cause a serious burden. This is not found persuasive because Group I and II are separate inventions as started in paragraph 2 of the restriction requirement and a restriction is proper when the product, that is, the claims of Group II, can be used in materially different process.

The requirement is still deemed proper and is therefore made FINAL.

Thus, claims 1-13 are examined and 14-41 are withdrawn from consideration

Double Patenting

2. A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101, which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101.

3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection

Art Unit: 1618

is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4. Claims 1-13 are provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claim 1-13 of copending Application No. 10/797,367. This is a provisional double patenting rejection since the conflicting claims have not in fact been patented.

5. Claims 1-13 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-13 of copending Application No. 10/780,452 in view of Chandrasekar et al. ("Platelets and Restenosis," in Journal of the American College of Cardiology, Vo. 35, No. 2, 2000, pp 555-562) or Miyazawa et al. ("Effects of pemirolast and tranilast on intimal thickening after arterial injury in the rat," in Journal of Cardiovascular Pharmacology, Vol. 30, no. 2, Aug. 1997, abstract).

The copending claims 1-13 of application number 10/780,452 use Pemirolast in the method for inhibiting post-operative adhesion while the examined claims use tranilast.

However, it is known in the art both tranilast and pemirolast are antiallergic agents known to reduce intimal thickening as disclosed by Chandrasekar (first full paragraph, left column of page

Art Unit: 1618

559) and Miyazawa (abstract). Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to use pemirolast to reduce intimal thickening. One having ordinary skill in the art would have been motivated to use tranilast or pemirolast to reduce intimal thickening with the expectation to either would reduce intimal thickening.

This is a provisional obviousness-type double patenting rejection.

Claim Rejections - 35 USC § 103

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

7. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

8. Claims 1-5 and 7-13 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Adachi et al. ("The prevention of Postoperative Intrapritoneal adhesions by Tranilast: N-(3',4'-dimethoxycinnamoyl) Anthranilic Acid).

Adachi discloses administration of tranilast that inhibits adhesion, post operatively and preoperatively; administration is oral and the recitation of systemic in claims 12 and 13 reads on oral; tranilast is administered melted and in combination with carboxymethyl cellulose sodium (left column 52, first full paragraph) so that Adachi meets the delivery vehicle of claims 2 and 3; the recitation of "amounts ... effective to inhibit formation of adhesion" represents any amount deemed effective by the artisan so that that requirement of claims 1 and 5; Adachi administers 60 mg/kg/per day, pre and post operatively, thus meeting claim 11; the recitation that the barrier is absorbable is a property of the barrier so that the teaching of Adachi that the tranilast is administered with the cellulose derivative, carboxymethyl cellulose sodium; meets the limitation of the barrier and thus meets claim 4; Adachi discloses that it is well known in the art that tranilast is effective drug for bronchial asthma, atopic dermatitis, allergic rhinitis, decreasing granulation, inhibit collagen synthesis of human cheloid tissue transplanted onto the backs of mice (page 52, under materials and methods); regarding claims 8-10, it is noted that Adachi teaches single dose per day administration and Adachi's silence on burst or sustained release of tranilast reflects an inherent teaching of either mode of release and the forms of release recited in claims 9 and 10 would flow from the composition that is administered and since Adachi administers the same composition as the claimed invention, it flows that the release of Adachi's formulation when administered meets the claimed release in claims 9 and 10. Regarding claim 7, one drug analog can be used in place of the other with the expectation of providing inhibitory effect on adhesions. While Adachi does not specifically state that the tranilast is administered directly to tissue surfaces in the body, it flows that oral administration of liquid or solution composition places the liquid or solution in direct contact with tissue surfaces so that the claims

Art Unit: 1618

are met. In the alternate, it is obvious that the liquid or solution formulation bathes the tissue surfaces in the body when administered.

9. Claims 1-13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Adachi et al. ("The prevention of Postoperative Intrapritoneal adhesions by Tranilast: N-(3',4'-dimethoxycinnamoyl) Anthranilic Acid) in view Hanson (US 6,376,242).

Claims 1-5 and 7-13 are rejected above. However, Adachi does not disclose the presence of other anti-inflammatory as recited in claim 6. But it is known according to Adachi that tranilast is effective drug for bronchial asthma, atopic dermatitis, allergic rhinitis, decreasing granulation, inhibit collagen synthesis of human cheloid tissue transplanted onto the backs of mice (page 52, under materials and methods). Hanson discloses that anti-inflammatory agents inhibit adhesions (column 5, lines 59 and 60) and that tranilast is an anti-cheloid agent that is known to reduce platelet count (column 15, lines 41, 67). Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to use tranilast to inhibit adhesion as taught by Adachi. One having ordinary skill in the art would have been motivated to use the combination of an anti-inflammatory agent and tranilast and expect the combination of the tranilast and the anti-inflammatory agent to inhibit adhesion.

10. The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Blessing M. Fubara whose telephone number is (571) 272-0594. The examiner can normally be reached on 7 a.m. to 5:30 p.m. (Monday to Thursday).

Art Unit: 1618

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Blessing Fubara
Patent Examiner
Tech. Center 1600

A handwritten signature in black ink, appearing to read "Blessing Fubara", is written over the printed name.